FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892261352> ?p ?o ?g. }

• W2892261352 endingPage "303" @default.
• W2892261352 startingPage "295" @default.
• W2892261352 abstract "Chronic central serous chorioretinopathy (CSCR) is poorly understood. Fluid accumulates in the subretinal space and retinal pigment epitheliopathy and neurosensory atrophy may develop. Permanent vision loss occurs in approximately one third of cases. There are no effective treatments for CSCR. Recent studies have shown the mineralocorticoid receptor antagonist, eplerenone, to be effective in resolving subretinal fluid and improving visual acuity. This trial aims to compare the safety and efficacy of eplerenone in patients with CSCR in a double-masked randomised placebo-controlled trial.Patients are randomised 1:1 to receive eplerenone with usual care or placebo with usual care for 12 months; 25 mg per day for 1 week, then 50 mg per day up to 12 months (unless discontinued for safety or resolution of CSCR). Key eligibility criteria are: age 18-60 years, one eye with CSCR for ≥4 months duration, best-corrected visual acuity (BCVA) >53 and <86 letters and no previous treatment. The primary outcome is BCVA at 12 months. Secondary outcomes include resolution of subretinal fluid, development of macular atrophy, subfoveal choroidal thickness, changes in low luminance visual acuity, health-related quality of life and safety.Recruitment is complete but was slower than expected. We maintained the eligibility criteria to ensure participants had 'true' CSCR and recruited additional centres. Effective distribution of the investigational medicinal product (IMP) was achieved by implementing a database to manage ordering and accountability of IMP packs. The results will provide adequately powered evidence to inform clinical decisions about using eplerenone to treat patients with CSCR." @default.
• W2892261352 created "2018-09-27" @default.
• W2892261352 creator A5002940859 @default.
• W2892261352 creator A5007945636 @default.
• W2892261352 creator A5008059536 @default.
• W2892261352 creator A5014460712 @default.
• W2892261352 creator A5016950875 @default.
• W2892261352 creator A5019521414 @default.
• W2892261352 creator A5027679064 @default.
• W2892261352 creator A5066434934 @default.
• W2892261352 creator A5067894246 @default.
• W2892261352 creator A5072541133 @default.
• W2892261352 creator A5080480919 @default.
• W2892261352 date "2018-09-07" @default.
• W2892261352 modified "2023-10-18" @default.
• W2892261352 title "Clinical efficacy of eplerenone versus placebo for central serous chorioretinopathy: study protocol for the VICI randomised controlled trial" @default.
• W2892261352 cites W1985548560 @default.
• W2892261352 cites W1989114914 @default.
• W2892261352 cites W1995086395 @default.
• W2892261352 cites W1997673578 @default.
• W2892261352 cites W2006529377 @default.
• W2892261352 cites W2023598701 @default.
• W2892261352 cites W2031856295 @default.
• W2892261352 cites W2034900382 @default.
• W2892261352 cites W2048638761 @default.
• W2892261352 cites W2068742492 @default.
• W2892261352 cites W2075557479 @default.
• W2892261352 cites W2099895047 @default.
• W2892261352 cites W2121841214 @default.
• W2892261352 cites W2124415048 @default.
• W2892261352 cites W2151703860 @default.
• W2892261352 cites W2161946932 @default.
• W2892261352 cites W2734000371 @default.
• W2892261352 doi "https://doi.org/10.1038/s41433-018-0212-2" @default.
• W2892261352 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6367466" @default.
• W2892261352 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30194380" @default.
• W2892261352 hasPublicationYear "2018" @default.
• W2892261352 type Work @default.
• W2892261352 sameAs 2892261352 @default.
• W2892261352 citedByCount "13" @default.
• W2892261352 countsByYear W28922613522019 @default.
• W2892261352 countsByYear W28922613522020 @default.
• W2892261352 countsByYear W28922613522021 @default.
• W2892261352 countsByYear W28922613522022 @default.
• W2892261352 crossrefType "journal-article" @default.
• W2892261352 hasAuthorship W2892261352A5002940859 @default.
• W2892261352 hasAuthorship W2892261352A5007945636 @default.
• W2892261352 hasAuthorship W2892261352A5008059536 @default.
• W2892261352 hasAuthorship W2892261352A5014460712 @default.
• W2892261352 hasAuthorship W2892261352A5016950875 @default.
• W2892261352 hasAuthorship W2892261352A5019521414 @default.
• W2892261352 hasAuthorship W2892261352A5027679064 @default.
• W2892261352 hasAuthorship W2892261352A5066434934 @default.
• W2892261352 hasAuthorship W2892261352A5067894246 @default.
• W2892261352 hasAuthorship W2892261352A5072541133 @default.
• W2892261352 hasAuthorship W2892261352A5080480919 @default.
• W2892261352 hasBestOaLocation W28922613521 @default.
• W2892261352 hasConcept C118487528 @default.
• W2892261352 hasConcept C126322002 @default.
• W2892261352 hasConcept C141071460 @default.
• W2892261352 hasConcept C142724271 @default.
• W2892261352 hasConcept C168563851 @default.
• W2892261352 hasConcept C189135053 @default.
• W2892261352 hasConcept C204787440 @default.
• W2892261352 hasConcept C27081682 @default.
• W2892261352 hasConcept C2778257484 @default.
• W2892261352 hasConcept C2778525890 @default.
• W2892261352 hasConcept C2780072264 @default.
• W2892261352 hasConcept C535046627 @default.
• W2892261352 hasConcept C71924100 @default.
• W2892261352 hasConceptScore W2892261352C118487528 @default.
• W2892261352 hasConceptScore W2892261352C126322002 @default.
• W2892261352 hasConceptScore W2892261352C141071460 @default.
• W2892261352 hasConceptScore W2892261352C142724271 @default.
• W2892261352 hasConceptScore W2892261352C168563851 @default.
• W2892261352 hasConceptScore W2892261352C189135053 @default.
• W2892261352 hasConceptScore W2892261352C204787440 @default.
• W2892261352 hasConceptScore W2892261352C27081682 @default.
• W2892261352 hasConceptScore W2892261352C2778257484 @default.
• W2892261352 hasConceptScore W2892261352C2778525890 @default.
• W2892261352 hasConceptScore W2892261352C2780072264 @default.
• W2892261352 hasConceptScore W2892261352C535046627 @default.
• W2892261352 hasConceptScore W2892261352C71924100 @default.
• W2892261352 hasIssue "2" @default.
• W2892261352 hasLocation W28922613521 @default.
• W2892261352 hasLocation W28922613522 @default.
• W2892261352 hasLocation W28922613523 @default.
• W2892261352 hasLocation W28922613524 @default.
• W2892261352 hasLocation W28922613525 @default.
• W2892261352 hasLocation W28922613526 @default.
• W2892261352 hasLocation W28922613527 @default.
• W2892261352 hasLocation W28922613528 @default.
• W2892261352 hasLocation W28922613529 @default.
• W2892261352 hasOpenAccess W2892261352 @default.
• W2892261352 hasPrimaryLocation W28922613521 @default.
• W2892261352 hasRelatedWork W1586374228 @default.
• W2892261352 hasRelatedWork W2003938723 @default.
• W2892261352 hasRelatedWork W2047967234 @default.

• next